The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel

Abstract Objective: Gestational diabetes mellitus (GDM) is associated with elevated risks of perinatal complications and type 2 diabetes mellitus, and screening and intervention can reduce these risks. We quantified the cost, health impact and cost-effectiveness of GDM screening and intervention in India and Israel, settings with contrasting epidemiologic and cost environments. Methods: We developed a decision-analysis tool (the GeDiForCE™) to assess cost-effectiveness. Using both local data and published estimates, we applied the model for a general medical facility in Chennai, India and for the largest HMO in Israel. We computed costs (discounted international dollars), averted disability-adjusted life years (DALYs) and net cost per DALY averted, compared with no GDM screening. Results: The programme costs per 1000 pregnant women are $259 139 in India and $259 929 in Israel. Net costs, adjusted for averted disease, are $194 358 and $76 102, respectively. The cost per DALY averted is $1626 in India and $1830 in Israel. Sensitivity analysis findings range from $628 to $3681 per DALY averted in India and net savings of $72 420–8432 per DALY averted in Israel. Conclusion: GDM interventions are highly cost-effective in both Indian and Israeli settings, by World Health Organization standards. Noting large differences between these countries in GDM prevalence and costs, GDM intervention may be cost-effective in diverse settings.

[1]  P. Damm,et al.  Gestational diabetes mellitus: results from a survey of country prevalence and practices , 2012, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[2]  C. Pettker,et al.  Screening for Gestational Diabetes Mellitus: Are the Criteria Proposed by the International Association of the Diabetes and Pregnancy Study Groups Cost-Effective? , 2012, Diabetes Care.

[3]  B. Duncan,et al.  Lesser than diabetes hyperglycemia in pregnancy is related to perinatal mortality: a cohort study in Brazil , 2011, BMC pregnancy and childbirth.

[4]  W. Herman.  The economics of diabetes prevention. , 2011, The Medical clinics of North America.

[5]  M. Mugglestone,et al.  Screening for gestational diabetes mellitus: cost–utility of different screening strategies based on a woman’s individual risk of disease , 2011, Diabetologia.

[6]  S. Shah,et al.  Gestational Diabetes Mellitus: Simplifying the International Association of Diabetes and Pregnancy Diagnostic Algorithm Using Fasting Plasma Glucose , 2010, Diabetes Care.

[7]  S. Shah,et al.  Gestational diabetes: simplifying the IADPSG diagnostic algorithm using fasting plasma glucose , 2010 .

[8]  H. Bastian,et al.  Effects of treatment in women with gestational diabetes mellitus: systematic review and meta-analysis , 2010, BMJ : British Medical Journal.

[9]  T. Einarson,et al.  Cost-of-illness study of type 2 diabetes mellitus in Colombia. , 2009, Revista panamericana de salud publica = Pan American journal of public health.

[10]  A. Hingorani,et al.  Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis , 2009, The Lancet.

[11]  Rita Furst Seifert,et al.  Distinguishing the economic costs associated with type 1 and type 2 diabetes. , 2009, Population health management.

[12]  C. Cameron,et al.  Cost-effectiveness of insulin analogues for diabetes mellitus , 2009, Canadian Medical Association Journal.

[13]  S. Fowler,et al.  Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. , 2008, The Journal of clinical endocrinology and metabolism.

[14]  A. Dyer,et al.  Hyperglycemia and adverse pregnancy outcomes. , 2008, The New England journal of medicine.

[15]  Torben Hansen,et al.  High Prevalence of Type 2 Diabetes and Pre-Diabetes in Adult Offspring of Women With Gestational Diabetes Mellitus or Type 1 Diabetes , 2008, Diabetes Care.

[16]  T. Gilmer,et al.  Cost-effectiveness of diabetes case management for low-income populations. , 2007, Health services research.

[17]  R. Singal,et al.  Developmentally regulated demethylase activity targeting the betaA-globin gene in primary avian erythroid cells. , 2007, Biochemistry.

[18]  A. M. Salinas-Martínez,et al.  Gestational diabetes: Validity of ADA and WHO diagnostic criteria using NDDG as the reference test. , 2006, Diabetes research and clinical practice.

[19]  J. Nolan,et al.  The cost of treating type 2 diabetes (CODEIRE). , 2006, Irish medical journal.

[20]  M. Abrahamson,et al.  Medicare coverage for patients with diabetes. A national plan with individual consequences. , 2006, Journal of general internal medicine.

[21]  C. Snehalatha,et al.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) , 2006, Diabetologia.

[22]  N. Cheung,et al.  Gestational diabetes in Iran: incidence, risk factors and pregnancy outcomes. , 2005, Diabetes research and clinical practice.

[23]  O. Langer,et al.  Gestational diabetes: the consequences of not treating. , 2005, American journal of obstetrics and gynecology.

[24]  M. Hod,et al.  Induction of labor in pregnancies with suspected large-for-gestational-age fetuses and unfavorable cervix. , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[25]  T. Hansen,et al.  Increasing incidence of diabetes after gestational diabetes: a long-term follow-up in a Danish population. , 2004, Diabetes care.

[26]  Catherine Kim,et al.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review. , 2002, Diabetes care.

[27]  Xilin Yang,et al.  Women with impaired glucose tolerance during pregnancy have significantly poor pregnancy outcomes. , 2002, Diabetes care.

[28]  J. Orgiazzi,et al.  Cost-effectiveness analysis of gestational diabetes mellitus screening in France. , 2002, European journal of obstetrics, gynecology, and reproductive biology.

[29]  J. Caro,et al.  Lifetime costs of complications resulting from type 2 diabetes in the U.S. , 2002, Diabetes care.

[30]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002, The New England journal of medicine.

[31]  A. Bagust,et al.  An economic model of the long-term health care burden of Type II diabetes , 2001, Diabetologia.

[32]  R. Hanson,et al.  Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. , 2000, Diabetes.

[33]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[34]  D. Fernando,et al.  The prevalence of gestational diabetes in a Sri Lankan antenatal clinic. , 1998, The Ceylon medical journal.

[35]  Dean T. Jamison,et al.  World development report 1993 : investing in health , 1993 .

[36]  J. O'sullivan.  Diabetes Mellitus After GDM , 1991, Diabetes.

[37]  S. Wilson.  Methods for the economic evaluation of health care programmes , 1987 .

[38]  A. Dyer,et al.  Hyperglycemia and Adverse Pregnancy Outcomes The HAPO Study Cooperative Research Group , 2011 .

[39]  J. Dungan,et al.  Hyperglycemia and Adverse Pregnancy Outcomes , 2009 .

[40]  R. Goldberg,et al.  Elective cesarean section to prevent anal incontinence and brachial plexus injuries associated with macrosomia—a decision analysis , 2004, International Urogynecology Journal.

[41]  Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. , 2003, Diabetes care.

[42]  B. Jönsson.  Revealing the cost of Type II diabetes in Europe. , 2002, Diabetologia.

[43]  L. Agodoa,et al.  United States Renal Data System (USRDS). , 2000, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[44]  BOMBAY CALCUrIA,et al.  World development report 1993--investing in health. , 1993, Communicable disease report. CDR weekly.

[45]  Target Population: Members of the DPP cohort 25 years of age or older with impaired glucose tolerance. Time Horizon: Lifetime. Perspectives: Health system and societal. Interventions: Intensive lifestyle, metformin, and placebo interventions , 2022 .